Table 4

Adjuvant chemotherapy and patient/tumour characteristics
pT1a, pT1b total patients (N = 402) Patients treated with adjuvant chemotherapy (N = 127)*
Distribution by age
18–34 7/402 (1.7%) 6/7 (85.7%)
35–49 85/402 (21.1%) 46/85 (54.1%)
50–69 230/402 (57.2%) 67/230 (29.1%)
≥ 70 80/402 (19.9%) 8/80 (10.0%)
Menopausal status
Pre- 101/402 (25.1%) 52/101 (51.5%)
Post- 293/402 (72.8%) 72/293 (24.6%)
Unknown 8/402 (2.0%) 3/8 (37.5%)
Grading
G1 101/402 (25.1%) 9/101 (8.9%)
G2 221/402 (55.0%) 66/221 (29.8%)
G3 72/402 (17.9%) 49/72 (68.0%)
Unknown 8/402 (2.0%) 3/8 (37.5%)
Proliferation index (Ki-67/MB1)
0–18% 283/402 (70.6%) 55/283 (19.4%)
19–29% 52/402 (12.9%) 28/53 (52.8%)
≥ 30% 54/402 (13.4%) 41/54 (75.9%)
Unknown 13/402 (3.2%) 3/13 (23.0%)
ER status
ER positive (≥ 10%) 351 /402(87.3%) 82/351(23.6%)
ER negative (0–9%) 51/402(12.7%) 45/51 (88.2%)
Hormonal status*
ER and/or PgR positive 354 /402 (74.6%) 84/354 (24.0%)
ER and PgR negative 48/402 (25.4%) 43/48 (89.6%)
HER2 status**
Positive 49/402 (12.2%) 36/49 (73.5%)
Negative 344/402 (85.6%) 90/344 (26.2%)
Missing 9/402 (2.2%) 1/9 (11.1%)
pN status
pN0 319/402 (79.4%) 72/319 (22.6%)
pN1 (1–3) 74/402 (18.4%) 47/74 (63.5%)
pN2 (4–9) 6/402(1.5%) 5/6 (83.3%)
pN3 (≥ 10) 3/402 (0.7%) 3/3 (100%)

* cut off: 10%

** HER2 status positive if: IHC 3+; or IHC 2+ and amplified by FISH,SISH,CISH; or amplified by FISH,SISH,CISH

Gori et al.

Gori et al. BMC Cancer 2012 12:158   doi:10.1186/1471-2407-12-158

Open Data